|Bid||517.00 x 0|
|Ask||650.00 x 0|
|Day's Range||516.80 - 516.80|
|52 Week Range||282.70 - 516.80|
|PE Ratio (TTM)||143.60|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Honeywell reported second quarter adjusted earnings per share and revenue that beat Wall Street Expectations.
All four of these names have very strong cash flows that allow them to not only pay better than 3% dividends, but also to buy back stock. Two are consumer staples, a sector that's been the S&P 500's second-best performer over the past month (up 3.83%). The others are in health care, which has been the S&P 500's No. 3 best sector (+3%) during the past month.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $1.27 billion.
Several major pharmaceutical companies lowered their spending on lobbyists in the second quarter of 2018, a time of uncertainty as President Donald Trump’s administration continued its campaign to lower drug costs for consumers. Pharmaceutical Research and Manufacturers of America spent $5.54 million between April and June, down 7.7 percent from the same period last year, according to disclosures released by the federal government on Friday. Companies including Johnson & Johnson and Bayer Corp. decreased their spending from the first quarter, when several companies set lobbying records amid the first signs of Trump’s moves to reduce out-of-pocket medicine costs.
Pfizer Inc. (pfe) said late Friday it received Food and Drug Administration approval to sell a biotech drug that is similar to Amgen Inc.'s (amgn) Neupogen. Pfizer's product is named Nivestym, which is intended to reduce the likelihood of infections in cancer patients receiving chemotherapy. In a statement, Pfizer said it expects to sell Nivestym at "a significant discount to the current wholesale acquisition cost" of Neupogen.
Johnson & Johnson (JNJ) announced its Q2 2018 earnings results on July 17. JNJ stock rose ~3.5% on the day and ended at a closing price of $129.12. On July 16, the stock closed at $124.69.
American depository receipts surged on Friday, July 20, following a Financial Times report that the pharmaceutical giant's chairman Philip Roy Hampton is mulling a breakup of the firm. Hampton is considering a split-up after some of the company's large shareholders urged the board to think about spinning off the consumer unit, the report stated. The publication added that Hampton has talked to some shareholders about creating a standalone pharmaceutical and vaccines firm in the medium term.
Pfizer Inc. (PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NIVESTYM™ (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference product.
Returns for the firm’s largest fund, Jensen Quality Growth (JENSX), continue to top the S&P 500, including over the past 10 years through June 30. Other large second-quarter moves include taking large cuts to positions in Nike (NKE) and Mastercard (MA), and trimming back in Coca-Cola (KO) and Microsoft (MSFT). Jensen hasn’t yet responded to a request for comment.
European drugmakers Roche , Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for nine key drugs by an average of 3 percent on July 1, but said it would hold off additional increases as discussions with the Trump administration continue over a longer-term solution to containing healthcare costs.
Pfizer Inc. started things off earlier this month by agreeing to roll back mid-year price hikes and delay them — for a few months. Similar efforts announced this week by Novartis AG and Merck & Co. arguably won’t be any more consequential. In a statement Friday, the Swiss pharmaceutical giant said it told the Health and Human Services Department on July 11 that it wouldn’t enact any more price hikes in 2018.
Last week, Pfizer Inc. (NYSE: PFE) announced plans to restructure the company and plans to deter price increases for as long as possible, assuming that Trump makes some changes. Merck announced Thursday that it will lower the price of several medications while also limiting future price increases. The price of several medications will drop by 10 percent, including Prinivil, Remeron and Trusopt, according to Merck.
Allergan’s stock price has fallen nearly 28.4% over the last 12 months, but it’s risen ~7.5% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~17.7% over the next 12 months.
European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.
Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.
There have been over 50 component changes to the Dow's since 1896, and these three stocks could be the next to join the prestigious index.
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
As the initial wave of healthcare companies unveil quarterly results, here are three takeaways from earnings calls. 1. Drugmakers are rethinking pricing strategies After Pfizer Inc. earlier this month said it would defer price hikes, Novartis AG said Wednesday, July 18, it will not raise prices for the rest of the year.
Merck & Co. said Thursday it will cut U.S. list prices for several of its drugs including the hepatitis C treatment Zepatier, and the company pledged to limit future net price increases. Merck, based in Kenilworth, N.J., said it was cutting prices “to help reduce patient out-of-pocket costs.” The price cuts will go into effect in the fall, a spokeswoman said.
Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers. Amid heightened political scrutiny over the high cost of prescription medicines and promises by Trump that drug price reductions were coming, New Jersey-based Merck became the first major drugmaker to announce voluntary price decreases. In addition to slashing the price of Zepatier, which owns a very small share of the hepatitis market, Merck said it would lower the list price by 10 percent of six other older drugs with minuscule sales.
Celgene’s (CELG) Abraxane reported revenue of $262 million in the first quarter, reflecting an ~11.0% YoY (year-over-year) rise. Abraxane’s sales grew 12.0% in the US market to reach $159.0 million. In the international market, its sales grew 9.6% to reach $103 million. Otezla and other drugs’ revenue trends
AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.